Compare Bandwidth Inc (BAND) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Cytokinetics Inc — how do they compare? Bandwidth Inc trades at $52.18 (market cap $1.66B), while Cytokinetics Inc trades at $76.62 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 6.4× Bandwidth Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Bandwidth Inc nearer its low. Which is the better fit depends on your goals.
| BAND | CYTK | |
|---|---|---|
Market Cap | $1.66B | $10.63B |
Sector | Technology | Technology |
52-Week High | $78.44 | $87.26 |
52-Week Low | $12.82 | $34.31 |
Enterprise Value | $2.04B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth Inc. (BAND) trades at $52.61, down 0.19% today, with a bullish technical trend per moving averages despite overbought RSI signals. Q2 2026 earnings beat expectations with $0.37 EPS, driven by 22% revenue growth and AI-driven communications demand. The company raised its 2026 outlook, highlighting strong enterprise adoption and a record 18.3% adjusted EBITDA margin.
Outlook is positive with 75% analyst buy ratings and a $75.25 consensus price target, but risks include high valuation (EV/EBITDA 34.08) and negative ROE. Earnings growth from AI integration and margin expansion supports upside, though profitability remains thin with a 0.27% net margin projected for 2026.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
